The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
It seems someone is accumulating shares at these low prices , near all-time lows causing the share price to repeatedly cross the 140 line . Whenever the share price starts to rise to the 140s, they target the BID to bring it back down and repeat the cycle. It's likely to rebound soon ; you can only squeeze so much from a dry lemon.
Recording of ITM POWER PLC Interim Results presentation, along with responses to questions that were answered by the company has just been published:
Link to the presentation:
https://www.investormeetcompany.com/investor/meeting/interim-results-273/presentation
Link to the Q&A :
https://www.investormeetcompany.com/meetings/interim-results-273
PRESENTERS:
Answered by:
Dennis Schulz - CEO
Andy Allen - CFO
Justin Scarborough - Head of Investor Relations
I watched the latest video call and they said the available cash is sufficient to cover them until probability early next year .
From the latest trading update :
Cash: $13.9m as of 31 December 2023
For the year ended December 31, Shield said it had delivered USD17.5 million in revenue, up nearly three-fold from USD6.2 million in 2022.
28 Sep 2023 RNS:
The Company is also pleased to announce that it has secured a US$20m senior secured debt facility from SWK (the "SWK Financing"), a life science-focused specialty finance company catering for small and mid-sized commercial-stage companies.
Did I read it correct?
- Retail Offer shall not exceed £200,000. ( available for individual shareholders- aka the minions)
-A placing and subscription to raise approximately £2.0 million - from whom?? The company’s Major shareholders? So I take it this placing isn’t available for individual shareholders ?
The rapid decline in share price coupled with AOP Health's significant stake as the company closed the year with total sales of $17.5 million, a significant increase from $6.2 million a year prior, largely driven by robust demand for its iron deficiency treatment, Accrufer, suggests to me a potential imminent takeover. If you examine this article, you'll notice parallels between the current scenario and the situations preceding AOP's takeovers of Amomed and SciPharm.
In May 2023, AOP Health made a cash takeover bid of £46.1 million (equivalent to 6.2 pence per share) for Shield Therapeutics plc (Shield), which represents twice the current share price. I am confident that if AOP Health were to make the same offer tomorrow, they would likely secure the necessary votes from the majority of other shareholders.
*AOP Orphan takes over two healthcare companies:
https://www.aop-health.com/global_en/press/press-releases/rare-disease-pioneer-aop-orphan-takes-over-two-health-care-companies-strengthening-its-position-in-europe-as-well-as-vienna-as-a-research-and-business-hub/
Frankie1x, we have several major shareholders, each holding less than 5% of the company's shares. This percentage serves as the requisite threshold for UK companies to inform the market of any changes in their holdings through a TR1 notification.
Jupiter Asset Management Ltd 4.364 %
Premier Fund Managers Ltd. 3.836 %
LGT Capital Partners AG (Investment Management) 3.669 %
KW Investment Management Ltd. 2.641 %
Jarvis Investment Management Ltd. 1.680 %
Given the substantial number of shares traded at the end of last month, I am inclined to believe that at least two major shareholders have offloaded their shares to the market and cashed out.
Regardless, the past is behind us, and we've observed a nice buying momentum gaining traction since the start of this week. I can see the share price smoothly rise back to the 4s from its current level. The technical chart is currently indicating a significant oversold condition on both the weekly and daily charts, making it an appealing prospect for chart and momentum traders as well.
Tax-loss harvesting strategy:
Selling shares at a loss before the end of the tax year allows holders to offset capital gains and reduce their overall taxable income. This strategy, known as tax-loss harvesting, helps minimize taxes by utilizing investment losses to counterbalance gains elsewhere in their portfolio.
Here you go :
https://www.youtube.com/watch?v=ZPjiX-VY3Cg
22 Feb 2024
Gateshead-based commercial stage pharmaceutical firm Shield Therapeutics has revised its breakeven plans, but hailed a period of progress.
In a trading update for the year ended 31 December 2023, Shield Therapeutics said that it expects to turn cash flow positive in the second half of 2025, instead of its initial target of year-end 2024.
The update follows the company identifying that its projection methodology used by its third-party data provider had resulted in an overstatement of total prescriptions in 2023.
"This development was partly responsible for the group not achieving previously indicated guidance of total prescriptions in FY23 of 100k to 130k", Shield said.
"With these revised prescription numbers, Shield is revisiting its previously communicated guidance and plans to provide additional updates at the time of the company's final results, expected to be published in April 2024", it added.
In spite of this, total 2023 revenue and income stood at $17.5m, which was a 2.8x increase over FY22.
Cash at the end of December was $13.9m.
Chief executive Greg Madison said: "The progress made in the market in 2023 has shown us that the opportunity for Accrufer continues to be significant.
"Quarterly prescription numbers grew throughout the year and we saw a significant improvement in the average net selling price in the second half.
"I'm also excited our new CFO, Santosh Shanbhag, has joined the team bringing both strategic and financial leadership to our organisation. Our partnership with Viatris continues to progress very well and we remain steadfast in our goal to make Accrufer the oral iron of choice for patients."
Link: https://shorturl.at/twCD5